<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4142</journal-id>
<journal-title><![CDATA[Revista Costarricense de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. costarric. cardiol]]></abbrev-journal-title>
<issn>1409-4142</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-41422017000100005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Anticoagulación en pacientes con fibrilación auricular. ¿Qué dicen las recomendaciones de las guías de práctica clínica?]]></article-title>
<article-title xml:lang="en"><![CDATA[Anticoagulation in patients with atrial fibrillation. What do clinical practice recommendations guidelines say?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Juanatey]]></surname>
<given-names><![CDATA[José R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez Álvarez]]></surname>
<given-names><![CDATA[Belén]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Santiago Compostela  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Clínico Universitario de Santiago de Compostela Servicio de Cardiología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>19</volume>
<numero>1-2</numero>
<fpage>5</fpage>
<lpage>8</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-41422017000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-41422017000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-41422017000100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La fibrilación auricular es una de las cardiopatías con mayor prevalencia. Para escoger la terapia ideal se debe evaluar el riesgo hemorrágico con la escala de HASBLED y el riesgo de sufrir un evento cerebrovascular con la escala del CHADS VASC. Se recomienda utilizar el algoritmo de las guías ESC 2016 para prevención de un ictus por fibrilación auricular, donde los NOAC deben preferirse a los antagonistas de la vitamina K]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Anticoagulation in patients with atrial fibrillation. What do clinical practice recommendations guidelines say? Atrial fibrillation is one of the most prevalent heart disease. In order to choose the ideal therapy, the risk of hemorrhagic risk should be evaluated with the HASBLED score and the risk of suffering a cerebrovascular event with the CHADSVASC score. It is recommended to use the algorithm of ESC 2016 guidelines for the prevention of stroke in atrial fibrillation, where NOAC should be preferred to vitamin K antagonists.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[anticoagulación]]></kwd>
<kwd lng="es"><![CDATA[guías terapéuticas]]></kwd>
<kwd lng="en"><![CDATA[atrial fibrilacion]]></kwd>
<kwd lng="en"><![CDATA[anticoagulation]]></kwd>
<kwd lng="en"><![CDATA[guidelines]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Doblas]]></surname>
<given-names><![CDATA[JJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2014</year>
<volume>67</volume>
<page-range>259-69</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da.]]></surname>
<given-names><![CDATA[Lane]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>126</volume>
<page-range>860-5</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Stroke Organisation (ESO)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>1609-78</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
